REGISTRATION

ISN-KDIGO Webinar: Glomerular Diseases Guideline Webinar – Part 2

Two prominent investigators in the areas of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS), and members of the KDIGO Glomerular Diseases Guideline Working Group, will discuss the recommended approaches to management of these diseases. FSGS is a pathologic lesion and not a disease. While this is well known, clinical trials have generally included any patient with FSGS, and this has likely contributed to the lack of development effective therapies. Correctly framing the heterogeneity of FSGS is the foundation of therapeutic development. For LN, standard therapies are modestly effective, but a significant number of patients do not respond. Learning from past trials, two recently successful clinical trials have led to the approval of two new drugs for LN. The next major step will be to understand how to use these new LN therapies and who will benefit from them.

Learning objectives:

1. Understand the types of FSGS and which are amenable to immunosuppressive therapies and which may not be.

2. Understanding the use of glucocorticoids, immunosuppressives, and targeted therapies in LN

3. Become familiar with novel therapies that are being tested for LN and FSGS and how they will fit into the management schema for these GNs.